News Hot Pursuit

Biocon slides as Q3 PAT falls 7% on R&D cost, tax impact
24-Jan-20   09:40 Hrs IST

On a consolidated basis, net profit fell 6.6% to Rs 202.80 crore in Q3 December 2019 (Q3 FY20) from Rs 217.20 crore in Q3 December 2018 (Q3 FY19), due to higher R&D expenses and tax impact of an exceptional item. Profit before tax (PBT) stood at Rs 315.10 in Q3 FY20, up by 8.9% from Rs 289.30 crore in Q3 FY19.

Net profit margin fell to 11% in Q3 FY20 from 13% in Q3 FY19. Net sales rose 13.5% to Rs 1748.10 crore in Q3 FY20 as compared to Rs 1540.80 crore recorded in Q3 FY19.

Net R&D expenses surged 71% to Rs 131 crore year-on-year (YoY). Tax expenses jumped 83.94% to Rs 84.8 crore during the period under review.

Consolidated EBITDA stood at Rs 480 crore in Q3 December 2019, up by 18% from Rs 406 crore in Q3 December 2018. EBITDA margin rose to 27% in Q3 FY20 from 26% in Q3 FY19.

Offering details on segmental revenues, Biocon said that branded formulations' revenues fell 26% to Rs 157 crore in Q3 FY20 over Q3 FY19. Revenues from the biologics segment rose the most to Rs 588 crore, up 31% YoY. The small molecules business revenues rose 16% to Rs 544 crore and those of the research services segment recorded a growth of 11%, rising to Rs 519 crore in Q3 December 2019 over Q3 December 2018.

Commenting on the highlights, chairperson & managing director, Kiran Mazumdar-Shaw stated: We witnessed a strong revenue growth led by Biologics, Small Molecules and Research Services businesses. We continued our journey of increasing access to high quality biosimilars and commercialized our biosimilar Trastuzumab in U.S., Canada and many EU markets this quarter.

Importantly, we have initiated value unlocking of our biosimilars business with the dilution of a minority stake to True North for a primary equity investment of approximately $75 million, which gives a pre-money equity valuation of approximately $3 billion for Biocon Biologics. We plan to raise further capital at an opportune time in the near future, she added.

Biocon is an innovation-led global biopharmaceuticals company.

Powered by Capital Market - Live News

Attention Investors:
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. Prevent Unauthorized Transactions in your Demat account\Trading account: Update your Mobile Number with your Depository Participant\Exchange. Receive alerts on your Registered Mobile for all debit and other important transactions in your Demat account\Trading account directly from Depository\Exchange on the same day.........issued in the interest of investors.
Disclosure of Proprietary Account Trading by Members to Clients
Proprietary Trading Disclosure:In terms of provisions of the Rules, Bye-Laws and Business Rules of the Exchange and with reference to circular MCX/T&S/147/2016 dated May 17, 2016 regarding Disclosure of Proprietary Account Trading by broker to client.,Pursuant to SEBI Circular Number SEBI/MRD/SEC/Cir-42/2003 dated November 19, 2003 & SEBI/HO/CDMRD/DMP/CIR/P/2016/49 dated April 25, 2016 GOODWILL WEALTH MANAGEMENT PVT LTD. Discloses to its clients about its policies on proprietary trades. Goodwill does proprietary trading in the derivatives segment at MCX respectively.GOODWILL – SEBI Reg No. INZ000049087
Copyright © 2016 All rights Reserved GOODWILL
Designed, Developed and content powered by CMOTS Infotech ( ISO 9001:2015 certified )
Filing complaints on SEBI Complaint Redress System (SCORES)
– Easy & quick
  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name, PAN, Address, Mobile Number, E-mail ID.
  • Benefits:
    • Effective communication
    • Speedy redressal of the grievances.
You can file complaints on SCORES through